1. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score
- Author
-
Joan Brunet, Josep Tabernero, Mieke Van Hemelrijck, Salvatore Grisanti, Bruno Vincenzi, Isabel Ruiz-Camps, Juan Aguilar-Company, Daniela Ferrante, Oriol Mirallas, Amanda Jackson, Beth Russell, Ramon Salazar, Aleix Prat, Daniele Generali, Nadia Harbeck, Alberto Zambelli, Carlo Alberto Tondini, David J Pinato, Lorenza Rimassa, Armando Santoro, Neha Chopra, Tom Newsom-Davis, Gino M Dettorre, Saoirse Dolly, Angela Loizidou, John Chester, Uma Mukherjee, Mark Bower, Christopher C T Sng, Alexia Bertuzzi, Ricard Mesia, Ailsa Sita-Lumsden, Elia Seguí, Federica Biello, Pavetha Seeva, Gianpiero Rizzo, Michela Libertini, Antonio Maconi, Charlotte Moss, Rossella Bertulli, Diego Ottaviani, Raquel Liñan, Andrea Marrari, M Carmen Carmona-García, Valeria Tovazzi, Vittoria Fotia, Claudia Andrea Cruz, Nadia Saoudi-Gonzalez, Eudald Felip, Ariadna Roqué, Alvin J X Lee, David García-Illescas, Roxana Reyes, Yien Ning Sophia Wong, Lorenza Scotti, Javier Marco-Hernández, Andrea Patriarca, Lorenzo Chiudinelli, Michela Franchi, Alessandra Gennari, and Nikolaos Diamantis
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background Patients with cancer are particularly susceptible to SARS-CoV-2 infection. The systemic inflammatory response is a pathogenic mechanism shared by cancer progression and COVID-19. We investigated systemic inflammation as a driver of severity and mortality from COVID-19, evaluating the prognostic role of commonly used inflammatory indices in SARS-CoV-2-infected patients with cancer accrued to the OnCovid study.Methods In a multicenter cohort of SARS-CoV-2-infected patients with cancer in Europe, we evaluated dynamic changes in neutrophil:lymphocyte ratio (NLR); platelet:lymphocyte ratio (PLR); Prognostic Nutritional Index (PNI), renamed the OnCovid Inflammatory Score (OIS); modified Glasgow Prognostic Score (mGPS); and Prognostic Index (PI) in relation to oncological and COVID-19 infection features, testing their prognostic potential in independent training (n=529) and validation (n=542) sets.Results We evaluated 1071 eligible patients, of which 625 (58.3%) were men, and 420 were patients with malignancy in advanced stage (39.2%), most commonly genitourinary (n=216, 20.2%). 844 (78.8%) had ≥1 comorbidity and 754 (70.4%) had ≥1 COVID-19 complication. NLR, OIS, and mGPS worsened at COVID-19 diagnosis compared with pre-COVID-19 measurement (p
- Published
- 2021
- Full Text
- View/download PDF